CTSO vs. INGN, NNOX, INFU, CV, ELMD, BSGM, CVRX, KRMD, SGHT, and STIM
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Inogen (INGN), Nano-X Imaging (NNOX), InfuSystem (INFU), CapsoVision (CV), Electromed (ELMD), Biosig Technologies (BSGM), CVRx (CVRX), KORU Medical Systems (KRMD), Sight Sciences (SGHT), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry.
Cytosorbents vs. Its Competitors
Cytosorbents (NASDAQ:CTSO) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.
In the previous week, Cytosorbents had 1 more articles in the media than Inogen. MarketBeat recorded 1 mentions for Cytosorbents and 0 mentions for Inogen. Inogen's average media sentiment score of 0.60 beat Cytosorbents' score of 0.00 indicating that Inogen is being referred to more favorably in the news media.
Cytosorbents presently has a consensus price target of $5.50, indicating a potential upside of 458.94%. Inogen has a consensus price target of $11.00, indicating a potential upside of 27.17%. Given Cytosorbents' higher probable upside, equities research analysts clearly believe Cytosorbents is more favorable than Inogen.
Cytosorbents has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.
Cytosorbents has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 6.6% of Cytosorbents shares are held by company insiders. Comparatively, 1.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Inogen has a net margin of -7.58% compared to Cytosorbents' net margin of -25.58%. Inogen's return on equity of -13.77% beat Cytosorbents' return on equity.
Summary
Cytosorbents and Inogen tied by winning 7 of the 14 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
This page (NASDAQ:CTSO) was last updated on 10/6/2025 by MarketBeat.com Staff
